. 2012 Dec 26;7(12):e52451. doi: 10.1371/journal.pone.0052451

Table 1. Pharmacology of the T618I hERG mutant studied with conventional voltage clamp.

Drug	WT I_hERG IC₅₀ (µM)	WT I_hERG n_H	T618I I_hERG IC₅₀(µM)	T618I I_hERG n_H	Fold IC₅₀
Quinidine	0.64 (C.I 0.51–0.79)	0.65 (C.I 0.55–0.75)	0.88 (C.I 0.41–1.88)	0.41 (C.I 0.25–0.57)	1.4 (0.8–2.4)
Disopyramide	7.68 (C.I 6.32–9.34)	0.87 (C.I 0.66–1.07)	16.83 (C.I 8.56–33.09)	0.47 (C.I 0.30–0.64)	2.2 (1.4–3.5)
D-Sotalol	112.2 (C.I 91.7–137.3)	0.74 (C.I 0.57–0.91)	356.6 (C.I 305.6–416.1)	0.85 (C.I 0.70–1.00)	3.2 (3.0–3.3)
Flecainide	1.87 (C.I 1.56–2.25)	0.81 (C.I 0.68–0.94)	4.67 (C.I 3.06–7.13)	0.58 (C.I 0.45–0.71)	2.5 (2.0–3.2)

IC₅₀ and n_H values shown are derived from fits to concentration-response relations in Figures 5 and 6, obtained from fractional inhibition of I_hERG using a voltage step protocol (shown in Figures 5A and 6A). Columns show mean values and 95% confidence intervals (C.I). The right-hand column expresses the ratio of the T618I IC₅₀ to the WT IC₅₀ value, to one decimal place. The numbers in parentheses in the right hand column represent the range of ratio values for the ± C.Is for derived T618/WT IC₅₀s.